856691-93-5

Basic information

• Product Name: CEP-11981
• Synonyms: CEP-11981;BOL 303213X;AEULIVPVIDOLIN-UHFFFAOYSA-N
• CAS NO: 856691-93-5
• Molecular Formula: C28H27N7O
• Molecular Weight: 477.56
• Mol File: 856691-93-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CEP-11981(CAS DataBase Reference)
• NIST Chemistry Reference: CEP-11981(856691-93-5)
• EPA Substance Registry System: CEP-11981(856691-93-5)

Safety Data

• Hazardous Substances Data: 856691-93-5(Hazardous Substances Data)

Usage

Description

CEP-11981, also known as tert-butyl (E)-4-(2-fluoro-4-hydroxy-5-methoxyphenyl) but-3-enoate, is a chemical compound belonging to the class of esters. It is recognized for its anti-inflammatory and anti-proliferative properties, which position it as a promising candidate for the development of new medicinal drugs. Its distinctive molecular structure and functional groups contribute to its value as a building block for the production of various biologically active compounds.

Uses

Used in Pharmaceutical Industry:
CEP-11981 is used as an intermediate in the synthesis of pharmaceuticals for its potential role in developing new medicinal drugs. Its anti-inflammatory and anti-proliferative properties make it a candidate for the treatment of various conditions that involve inflammation and uncontrolled cell growth.
Used in Agrochemical Industry:
CEP-11981 is also utilized as an intermediate in the synthesis of agrochemicals, where its unique properties can be harnessed to develop new compounds for agricultural applications, potentially improving crop protection and yield.
Further research is necessary to fully explore the potential applications and benefits of CEP-11981 in both the pharmaceutical and agrochemical fields, as well as in other areas of drug discovery and development.

Upstream product

• 855260-38-7 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-amino-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one 
• 64-19-7 acetic acid 
• 4595-60-2 2-bromopyrimidine 
• 856694-02-5 5-cyano-2,10,11,12-tetrahydro-2-methyl-indazolo[5,4-a]carbazole-4-carboxylic acid ethyl ester 
• 936017-05-9 5-cyano-11,12-dihydro-2-methyl-10-(2-methylpropyl)indazolo[5,4-a]carbazole-4-carboxylic acid ethyl ester 
• 1722-12-9 2-chloropyrimidine 
• 936017-17-3 5-cyano-10-isobutyl-2-methyl-7-nitro-2,10,11,12-tetrahydro-1,2,10-triaza-indeno[5,4-a]fluorene-4-carboxylic acid ethyl ester 

Relevant articles and documents

Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-Methylpropyl)-12, 13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4 H -indazolo[5,4-a]pyrrolo[3,4-c] carbazol-4-one (CEP-11981): A novel oncology therapeutic agent

A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor-induced angiogenesis and inhibition of primary and metastatic tumor growth in a variety of solid and hematopoietic tumors. Given the requirement of tumors for different cytokine and growth factors at distinct stages of their growth and dissemination, optimal antiangiogenic therapy necessitates inhibition of multiple, complementary, and nonredundant angiogenic targets. 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8- (pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (11b, CEP-11981) is a potent orally active inhibitor of multiple targets (TIE-2, VEGF-R1, 2, and 3, and FGF-R1) having essential and nonredundant roles in tumor angiogenesis and vascular maintenance. Outlined in this article are the design strategy, synthesis, and biochemical and pharmacological profile for 11b, which completed Phase I clinical assessing safety and pharmacokinetics allowing for the initiation of proof of concept studies.

Novel fused pyrrolocarbazoles

The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these f